Allogene Therapeutics (NASDAQ:ALLO) Given “Outperform” Rating at William Blair

William Blair restated their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO) in a research report sent to investors on Thursday,RTT News reports.

Other equities analysts also recently issued research reports about the company. Canaccord Genuity Group decreased their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Truist Financial reaffirmed a “buy” rating and issued a $14.00 target price (down from $17.00) on shares of Allogene Therapeutics in a research report on Friday, August 9th. Piper Sandler cut their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Thursday. Citigroup increased their price target on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Oppenheimer started coverage on Allogene Therapeutics in a research report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $9.73.

Allogene Therapeutics Price Performance

Shares of NASDAQ:ALLO opened at $2.27 on Thursday. The stock’s 50-day moving average is $2.75 and its 200 day moving average is $2.65. The company has a market cap of $475.95 million, a PE ratio of -1.46 and a beta of 0.84. Allogene Therapeutics has a 1 year low of $2.01 and a 1 year high of $5.78.

Institutional Trading of Allogene Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Headlands Technologies LLC purchased a new stake in Allogene Therapeutics during the 1st quarter valued at about $78,000. CANADA LIFE ASSURANCE Co increased its position in shares of Allogene Therapeutics by 85.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after acquiring an additional 8,162 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Allogene Therapeutics by 76.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,177,619 shares of the company’s stock worth $18,675,000 after acquiring an additional 1,806,147 shares during the last quarter. Bourgeon Capital Management LLC lifted its position in Allogene Therapeutics by 131.6% in the 2nd quarter. Bourgeon Capital Management LLC now owns 132,455 shares of the company’s stock valued at $309,000 after acquiring an additional 75,255 shares in the last quarter. Finally, Phoenix Wealth Advisors purchased a new stake in Allogene Therapeutics during the 2nd quarter valued at $30,000. 83.63% of the stock is owned by institutional investors.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).